Skip to content
26 October · 06:30 UTCFollow AstraZeneca by emailFollow

AZN · Pharma and healthcare · one day

AstraZeneca (AZN): news on Friday 23 October 2026

News from the 24 hours to Friday morning, 23 October 2026.

AstraZeneca dashboard

Tone of the day

+8.3strongly positive
Relevant headlines32of 40 read
Stories5grouped by event

What the score means. Each score rates how good or bad the news was for the company, from −10 (clearly bad) to +10 (clearly good). 0 is neutral, and anything beyond ±6 is strong and rare. It rates the coverage, not the share price.

Why it scored this way

Coverage was dominated by the FDA's accelerated approval of Ultomiris for IgA nephropathy and the US launch of the lung cancer drug Zegfrovy, both seen as clear positives. Shares were reported higher after results, and new AI partnerships with Oracle and Abu Dhabi Biobank added to the favourable tone, with only some mixed trial readouts as a drag.

What drove it

  • Ultomiris IgAN approval
  • Zegfrovy US launch
  • AI partnerships

Around this day

DayToneHeadlines
Sat 17 Oct+6.332
Sun 18 Oct+5.76
Mon 19 Oct+4.03
Tue 20 Oct+5.524
Wed 21 Oct+8.738
Thu 22 Oct+8.328
Fri 23 Oct+8.332
Sat 24 Oct+9.28
Sun 25 Oct+10.016
Mon 26 Oct+10.033

5 stories · 32 headlines · strongest first

Pharma and healthcare on 23 OctoberFTSE 100 that day
ToneHeadline and why it scored that wayOutlet
FDA grants accelerated approval to Ultomiris for IgA nephropathy +9.311 headlines today · 18 in all, since 22 October · Outlets report the FDA accelerated approval of Ultomiris in IgAN, its fifth indication.
+9.2AstraZeneca bags another US indication for Ultomiris with IgAN approvalAnother US indication for UltomirisPharmaceutical Technology
+9.2Astrazeneca's Ultomiris wins accelerated US approvalUltomiris wins accelerated US approvalSharecast
+9.2AstraZeneca Adds IgAN To Blockbuster Ultomiris With Accelerated ApprovalUltomiris gains IgAN accelerated approvalinsights.citeline.com
+9.2FDA approves fifth indication for AstraZeneca's Ultomiris, this time in IgA nephropathyFifth Ultomiris indication approved by FDAFirstWord Pharma
+9.2AZ's Ultomiris adds 5th rare disease feather to cap with FDA IgAN nodFifth rare disease indication for UltomirisFierce Pharma
+9.2AstraZeneca Gets Accelerated FDA Nod for Ultomiris in IgA NephropathyFDA accelerated nod for Ultomiris in IgANZacks Investment Research
+9.2FDA grants accelerated approval to AstraZeneca’s Ultomiris for rare kidney disease IgANFDA accelerated approval for Ultomiris in IgANIndian Pharma Post
+8.3AstraZeneca (LSE:AZN): What Does the New Ultomiris Approval Establish?New Ultomiris approval seen as positiveKalkine Media
+8.3US FDA gives AstraZeneca's Ultomiris accelerated approval to reduce proteinuria in IgANFDA accelerated approval to reduce proteinuria in IgANAllSci
+8.3AstraZeneca wins new FDA approval for serious kidney diseaseNew FDA approval for serious kidney diseaselifesciencesweden.se
+8.3FDA clears AstraZeneca’s Ultomiris for rare kidney diseaseFDA clears Ultomiris for rare kidney diseaseNews Ghana
AstraZeneca launches Zegfrovy for lung cancer in US +8.56 headlines today · Outlets report US availability of Zegfrovy (sunvozertinib) for EGFR exon 20 NSCLC after accelerated approval.
+9.2AstraZeneca Launches Targeted Lung Cancer Drug In US After FDA Accelerated ApprovalUS launch of lung cancer drug after approvalYahoo Finance
+8.3AstraZeneca launches ZEGFROVY for lung cancer in US By Investing.comZegfrovy lung cancer US launchInvesting.com UK
+8.3AstraZeneca launches sunvozertinib for EGFR exon 20 NSCLCSunvozertinib launched for EGFR exon 20 NSCLCStreetInsider
+8.3AstraZeneca's lung cancer drug is now available in the US; 46% responded in its trial.Lung cancer drug available in US with 46% responseStock Titan
+8.3AstraZeneca announces US availability of ZegfrovyUS availability of Zegfrovy announcedTipRanks
+8.3ZEGFROVY® (sunvozertinib) now available in the US for patients with previously treated non-small cell lung cancer with EGFR exon 20 insertion mutationsZegfrovy now available for previously treated NSCLCYahoo Finance
AstraZeneca share price moves +3.26 headlines today · Headlines report AstraZeneca stock up about 2.4–3% and discuss forecasts.
+7.5Why Is AstraZeneca Stock Trading Higher Today? - AstraZeneca (NYSE:AZN)Stock trading higher, positive moveBenzinga
+7.5AstraZeneca stock rises 2.4% as nine-month and third-quarter 2026 resultsStock up 2.4% after nine-month resultsTraders Union
+7.5AstraZeneca PLC Stock (AZN) Moved Up by 3.04% on Oct 22: A Full AnalysisShares moved up 3.04% on the dayNewsBreak: Local News & Alerts
−4.2Why Is AstraZeneca (LSE:AZN) Stock Wobbling This Week After Mixed Trial Readouts?Shares wobbling after mixed trial readoutsKalkine Media
+0.8AstraZeneca PLC (AZN) Stock ForecastsGeneric stock forecast page, little news contentYahoo Finance
+0.3AstraZeneca stock trades flat as buyers maintain support despite mixed momentum signalsStock flat with mixed momentum signalsTraders Union
AstraZeneca and Oracle launch global AI collaboration +5.85 headlines today · 38 in all, since 20 October · Outlets report the AstraZeneca–Oracle partnership on AI-enabled clinical trials.
+5.8AstraZeneca and Oracle Partner to Advance AI-Powered Clinical Trials and Patient CareOracle partnership on AI-powered clinical trialsEME Outlook Magazine
+5.8Oracle and AstraZeneca Collaborate to Advance AI-Enabled Clinical Trials and Patient RecruitmentOracle collaboration on AI-enabled trialsHLTH
+5.8AstraZeneca Bets on Oracle to Find Trial Patients FasterOracle tie-up to find trial patients fasterAIM Media House
+5.0Oracle and AstraZeneca Explore AI in HealthcareOracle AI healthcare collaborationVoice of Healthcare
+4.2Anne-Claire Gerbaldi։ Three AI Announcements in a Week, One Vision for AI at AstraZenecaPositive profile of AI strategy at AstraZenecaOncodaily
Abu Dhabi Biobank partners with AstraZeneca on predictive healthcare +5.84 headlines today · Outlets report the partnership to advance predictive healthcare and AI disease prediction.
+5.8Abu Dhabi Biobank, AstraZeneca Partner on Predictive HealthcarePredictive healthcare partnership with Abu Dhabi BiobankMarketScreener
+5.8AstraZeneca, Abu Dhabi Biobank to Explore AI Platform for Disease PredictionAI disease prediction collaboration with Abu Dhabi BiobankMarketScreener
+5.8Abu Dhabi Biobank partners with AstraZeneca to advance predictive healthcareBiobank partnership on predictive healthcarewam.ae
+5.8Abu Dhabi Biobank Partners With Astrazeneca To Advance Predictive Healthcare - AD Media OfficeAbu Dhabi Biobank partnership on predictive healthcareTradingView

Each headline has its own score; the links go to the publisher.

Follow by email

A short, free morning email on how the news treated AstraZeneca: the tone, the stories behind it, and when coverage starts to turn. Launching soon; one click to unsubscribe.

How it works. Every morning an AI model reads the UK business news about each FTSE 100 company and scores how good or bad it is for the company, from −10 to +10. Pages update by about 07:45 UK time.

Not investment advice. MarketFrame rates the tone of news coverage. It is general information, not a recommendation to buy or sell anything. The scores are not share-price data or forecasts: a good score doesn't mean a share will rise, and a bad one doesn't mean it will fall.

Data to 06:30 UTC, 26 October · 326 headlines · 63 companiesMade by Adapt Progress Evolve Limited, a UK company · Privacy · Terms · RSS · API · llms.txt